Joseph P. Lyssikatos - Aug 19, 2025 Form 4 Insider Report for Enliven Therapeutics, Inc. (ELVN)

Role
CHIEF SCIENTIFIC OFFICER
Signature
/s/ Ben Hohl, by power of attorney
Stock symbol
ELVN
Transactions as of
Aug 19, 2025
Transactions value $
-$248,217
Form type
4
Date filed
8/21/2025, 06:46 PM
Previous filing
Jul 23, 2025
Next filing
Sep 23, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER C/O ENLIVEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, BOULDER /s/ Ben Hohl, by power of attorney 2025-08-21 0001967150

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELVN Common Stock Sale -$98.1K -5K -0.52% $19.62 948K Aug 19, 2025 See footnote F1, F2, F3
transaction ELVN Common Stock Sale -$150K -7.5K -0.79% $20.01 940K Aug 21, 2025 See footnote F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.
F2 This transaction was executed in multiple trades at prices ranging from $19.0925 to $20.08. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.
F4 This transaction was executed in multiple trades at prices ranging from $20.00 to $20.11. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.